P-81 Phase 3 study of MK4280A (coformulated favezelimab and pembrolizumab) versus standard of care in previously treated PD-L1–positive metastatic colorectal cancer (mCRC)
| Autor: | Kim, T., Taieb, J., Passhak, M., Kim, S., Geva, R., Hofsli, E., Perl, G., Yalcin, S., Hubert, A., Somer, B., Wong, Z., Wang, A., Leconte, P., Fogelman, D., Heinemann, V. |
|---|---|
| Zdroj: | In Annals of Oncology June 2022 33 Supplement 4:S277-S277 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|